Fig. 2

Mean plasma concentration-time profiles of conteltinib (CT-707). A Plasma concentration-time curve of a single dose of conteltinib PK assessed in the PK lead-in phase of the dose-escalation phase at pre-dose and 0.5 h, 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, 12 h, 24 h, 48 h, 72 h, 96 h, 120 h, 144 h, and 168 h post-dose. B Plasma concentration-time curve of single-dose conteltinib PK assessed in cycle 1 day 1 of dose-expansion phase at pre-dose and 0.5 h, 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, 12 h, and 24 h post-dose. C Plasma concentration-time curve of conteltinib PK assessed in cycle 1 day 28 of dose-escalation phase at pre-dose and 0.5 h, 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, 12 h, 24 h post-dose. D Plasma concentration-time curve of conteltinib PK assessed in cycle 1 day 28 of dose-expansion phase at pre-dose and 0.5 h, 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, 12 h, 24 h post-dose. Data are mean (standard error of the mean). PK, pharmacokinetic; QD, quaque die; ALK, anaplastic lymphoma kinase; NSCLC, non-small cell lung cancer